Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Rhea-AI Summary

Sartorius Stedim Biotech S.A. announced that during its virtual Annual General Shareholders' Meeting, shareholders approved a dividend payment of 0.68 euros per share for fiscal 2020, translating to a total distribution of 62.7 million euros. This represents a doubling of the previous year's dividend of 0.34 euros per share. The meeting also saw a significant majority granting discharge to all directors. The company continues to see strong growth, employing over 7,500 individuals and reporting 1,910 million euros in sales revenue for 2020.

Positive

• Dividend increased from 0.34 euros to 0.68 euros per share.
• Total profit distributed of 62.7 million euros.
• Company's workforce has exceeded 7,500 employees.
• Sales revenue achieved was 1,910 million euros in 2020.

Negative

• None.

AUBAGNE, France, March 24, 2021 /PRNewswire/ -- At today's virtual combined Annual General Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of 0.68 euros per share for fiscal 2020. The total profit distributed will be 62.7 million euros. The previous year's dividend was 0.34 euros per share.

The Annual General Shareholders' Meeting granted discharge to all directors by a large majority.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

ASM documents
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/shareholders-meeting

Press images
https://www.sartorius.com/en/company/newsroom/downloads-publications

Financial calendar
April 21, 2021: Publication of first-quarter figures (January to March 2021) 
July 21, 2021: Publication of first-half figures (January to June 2021)
October 20, 2021: Publication of nine-month figures (January to September 2021)

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

Logo - https://mma.prnewswire.com/media/1472792/Sartorius_Logo.jpg

Contact:
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/resolutions-of-the-annual-shareholders-meeting-of-sartorius-stedim-biotech-sa-301255041.html

SOURCE Sartorius Stedim Biotech S.A.

FAQ

What is the dividend declared by Sartorius Stedim Biotech for fiscal 2020?

The declared dividend is 0.68 euros per share.

How much total profit will Sartorius Stedim Biotech distribute as dividends?

The total profit distributed will be 62.7 million euros.

What was the previous year's dividend per share for Sartorius Stedim Biotech?

The previous year's dividend was 0.34 euros per share.

When was the Annual General Shareholders' Meeting of Sartorius Stedim Biotech held?

The meeting was held on March 24, 2021.

What were the sales revenues of Sartorius Stedim Biotech in 2020?

The sales revenue for 2020 was 1,910 million euros.